Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Stress Disorder, Post Traumatic
Interventions
D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cataract Surgery, Sedation, Cognition Function, Perioperative Care, Older Adults
Interventions
Alprazolam, Midazolam
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

NCT00830024
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

NCT00829426
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Anxiety Disorder
Interventions
Alprazolam tablet, Alprazolam sublingual
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Generalized Anxiety Disorder
Interventions
Alprazolam (Xanax), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

NCT03286218
Conditions
Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
Interventions
Lasmiditan, Alprazolam, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

NCT00703885
Conditions
Anxiety Disorders
Interventions
0.25 mg alprazolam, 1.0 mg alprazolam, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Conditions
Food-drug Interaction
Interventions
Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg
Dietary Supplement · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Healthy
Interventions
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Panic Disorder
Interventions
placebo, alprazolam XR
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Hialeah, Florida • Jacksonville, Florida • North Miami, Florida + 15 more
Conditions
Healthy
Interventions
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Panic Disorder
Interventions
placebo, alprazolam XR
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
3
States / cities
Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin
Conditions
Cannabis Use Disorder
Interventions
THC, Alprazolam, Placebo oral capsule, CBD
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim

NCT04970342
Conditions
Driving Behavior, Driving Under the Influence
Interventions
Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD), Cannabis (0%/ THC / 0% CBD)
Drug
Lead sponsor
Timothy L. Brown
Other
Eligibility
19 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Healthy Volunteers
Interventions
Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Healthy Volunteer
Interventions
Alprazolam Placebo, Cenobamate placebo, Alprazolam, Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Not applicable Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

NCT00592332
Conditions
Type 1 Diabetes
Interventions
Alprazolam, control group
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Healthy
Interventions
alprazolam, Placebo, PF-00572778
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Healthy
Interventions
Alprazolam Extended-release Tablets 3 mg, Xanax XR® Tablets 3 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Alprazolam Abuse Liability

NCT00603980
Conditions
Abuse Liability of Staccato Alprazolam
Interventions
Inhaled placebo + oral placebo, Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, Oral alprazolam 1 mg, Oral alprazolam 2 mg, Oral alprazolam 4 m, Oral alprazolam 2 mg qualifying session, Oral placebo qualifying session
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland